Fast Five Quiz: Non–Small Cell Lung Cancer (NSCLC) and RET Mutation

Maurie Markman, MD

Disclosures

August 24, 2021

Targeted next-generation sequencing of DNA is now the standard of care for management of patients with lung adenocarcinoma, with the goal of identifying actionable genomic alterations that may guide choice of therapy. Predictive biomarkers in the setting of non–small cell lung cancer (NSCLC) include gene fusions in tumors that have rearranged during transfection (RET). In NSCLC, chromosomal rearrangements between the RET gene and another domain lead to overexpression of the RET protein. These gene fusions have been identified as oncogenic drivers in multiple tumor types. They have the potential to cause chimeric, cytosolic proteins with constitutively active RET kinase domain, leading to increased cell proliferation, migration, and survival.

How familiar are you with RET rearrangements in NSCLC? Test your knowledge with this quick quiz.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....